Heinrich Röder of Biodesix to Present at 2013 Biomarker Summit

BOULDER, Colo. -- (BUSINESS WIRE) -- Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Chief Technology Officer Heinrich Röder, DPhil, will present at the 6^th Oncology Biomarkers Conference as part of the Biomarker Summit 2013, being held March 20-22 in San Francisco. Dr. Röder will discuss how Biodesix’ high-throughput mass spectrometry technology, Deep MALDI™, is used to generate protein signatures for specific questions in oncology.

The presentation, “Disease States from Circulating Proteins,” will take place on Thursday, March 21 at 9:30 a.m. PDT. The session will look at circulating proteins as viable candidates for the characterization of the phenotypical state of an organism and how such characterization may provide a powerful tool to define novel disease states on a molecular basis.

“The new Deep MALDI technology allows for the simultaneous semi-quantitative measurement of thousands of proteins from serum and plasma,” said Dr. Röder. “During this session, we will review the analytical validation of this technology and the challenges that arise from the large amount of data generated to demonstrate how circulating proteins can aid in the detection, monitoring and treatment of disease.”

Deep MALDI is proprietary technology that harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to a therapy. Biodesix’ validated and commercialized serum proteomic test, VeriStrat^®, identifies patients who are likely to have good or poor outcomes after treatment for advanced lung cancer. Biodesix collaborates with clinical investigators and also partners with biotechnology and pharmaceutical companies to develop diagnostics that can determine which patients are most likely to benefit from novel therapies.

For more information about Biomarker Summit 2013 and details on the location of Dr. Röder’s presentation, visit www.GTCbio.com.

About Biodesix

Biodesix is a molecular diagnostics company advancing the development of innovative products for personalizing medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance which may lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein diagnostics based on their proprietary mass spectrometry based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’ first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’ CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents. For more information on VeriStrat, please visit www.VeriStratSupport.com. For more information about Biodesix, please visit www.Biodesix.com.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.